204 related articles for article (PubMed ID: 38683993)
1. Incomplete-penetrant hypertrophic cardiomyopathy
Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993
[TBL] [Abstract][Full Text] [Related]
2. Multi-scale models reveal hypertrophic cardiomyopathy MYH7 G256E mutation drives hypercontractility and elevated mitochondrial respiration.
Lee S; Roest ASV; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran S; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Spudich JA; Ruppel K; Mack D; Pruitt BL; Regnier M; Wu SM; Bernstein D
bioRxiv; 2023 Jun; ():. PubMed ID: 37333118
[TBL] [Abstract][Full Text] [Related]
3. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
[TBL] [Abstract][Full Text] [Related]
4. Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.
Vander Roest AS; Liu C; Morck MM; Kooiker KB; Jung G; Song D; Dawood A; Jhingran A; Pardon G; Ranjbarvaziri S; Fajardo G; Zhao M; Campbell KS; Pruitt BL; Spudich JA; Ruppel KM; Bernstein D
Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34117120
[TBL] [Abstract][Full Text] [Related]
5. Cardiomyocyte Apoptosis Is Associated with Contractile Dysfunction in Stem Cell Model of
Loiben AM; Chien WM; Friedman CE; Chao LS; Weber G; Goldstein A; Sniadecki NJ; Murry CE; Yang KC
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902340
[TBL] [Abstract][Full Text] [Related]
6. Multiplexed Functional Assessments of
Friedman CE; Fayer S; Pendyala S; Chien WM; Loiben A; Tran L; Chao LS; McKinstry A; Ahmed D; Farris SD; Stempien-Otero A; Jonlin EC; Murry CE; Starita LM; Fowler DM; Yang KC
Circ Genom Precis Med; 2024 Apr; 17(2):e004377. PubMed ID: 38362799
[TBL] [Abstract][Full Text] [Related]
7. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
[TBL] [Abstract][Full Text] [Related]
8. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
9. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
[TBL] [Abstract][Full Text] [Related]
10. Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy.
Kraft T; Montag J
Pflugers Arch; 2019 May; 471(5):719-733. PubMed ID: 30740621
[TBL] [Abstract][Full Text] [Related]
11. Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation.
Witjas-Paalberends ER; Ferrara C; Scellini B; Piroddi N; Montag J; Tesi C; Stienen GJ; Michels M; Ho CY; Kraft T; Poggesi C; van der Velden J
J Physiol; 2014 Aug; 592(15):3257-72. PubMed ID: 24928957
[TBL] [Abstract][Full Text] [Related]
12. Structural effects of the slow/b-cardiac myosin heavy chain R453C mutation in cardiac and skeletal muscle.
Tajsharghi H; Fyhr IM
Scand Cardiovasc J; 2008 Apr; 42(2):153-6. PubMed ID: 18365899
[TBL] [Abstract][Full Text] [Related]
13. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
14. Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.
Lowey S; Bretton V; Joel PB; Trybus KM; Gulick J; Robbins J; Kalganov A; Cornachione AS; Rassier DE
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):11238-11243. PubMed ID: 30322937
[TBL] [Abstract][Full Text] [Related]
15. Generation of a hiPSC line ZZUNEUi007-A from a patient with hypertrophic cardiomyopathy caused by mutation in MYH7.
Li X; Liu Y; Liu F; Wang X; Liu M; Du W; Zhao J; Wang M; Hu L; Wang C; Fu W; Dong J; Zhao X
Stem Cell Res; 2020 Mar; 43():101699. PubMed ID: 31931472
[TBL] [Abstract][Full Text] [Related]
16. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
[TBL] [Abstract][Full Text] [Related]
17. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations.
Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT
Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
19. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.
Nag S; Trivedi DV; Sarkar SS; Adhikari AS; Sunitha MS; Sutton S; Ruppel KM; Spudich JA
Nat Struct Mol Biol; 2017 Jun; 24(6):525-533. PubMed ID: 28481356
[TBL] [Abstract][Full Text] [Related]
20. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
Witjas-Paalberends ER; Piroddi N; Stam K; van Dijk SJ; Oliviera VS; Ferrara C; Scellini B; Hazebroek M; ten Cate FJ; van Slegtenhorst M; dos Remedios C; Niessen HW; Tesi C; Stienen GJ; Heymans S; Michels M; Poggesi C; van der Velden J
Cardiovasc Res; 2013 Aug; 99(3):432-41. PubMed ID: 23674513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
